# OnCo record paper-tjulandin-prolgolimab-miraculum-ejc-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-tjulandin-prolgolimab-miraculum-ejc-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-tjulandin-prolgolimab-miraculum-ejc-2021" ;
  schema:name "MIRACULUM: prolgolimab, the first Russian-developed anti-PD-1 antibody, in advanced melanoma"@en ;
  schema:description "The trial behind Russia's own PD-1 antibody: 126 patients with advanced melanoma, an objective response in 38 per cent on the fortnightly dose and 29 per cent on the three-weekly dose, and severe treatment-related side effects in 13 and 3 per cent."@en ;
  schema:url <https://onco.cc/key-papers/paper-tjulandin-prolgolimab-miraculum-ejc-2021/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.ejca.2021.02.030>, <https://pubmed.ncbi.nlm.nih.gov/33872982/>, <https://clinicaltrials.gov/study/NCT03269565> ;
  schema:sameAs <https://doi.org/10.1016/j.ejca.2021.02.030> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Tjulandin S, Demidov L, Moiseyenko V, et al." ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:drugs <https://onco.cc/drugs/bcd-100/> ;
  onco:companies <https://onco.cc/companies/biocad/> ;
  onco:journals <https://onco.cc/journals/european-journal-of-cancer/> .